New blood test detects 90% of aggressive prostate cancer cases, beating current screenings

Stockholm3 blood test detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests in a study of over 12,000 men in Sweden.
Morningstar

Foundation Medicine Announces Expanded Participation in National Cancer Institute’s ComboMATCH Platform Trials Through Inclusion of Its High-Quality Blood-Based Biomarker ...

Foundation Medicine Announces Expanded Participation in National Cancer Institute’s ComboMATCH Platform Trials Through Inclusion of Its High-Quality Blood-Based Biomarker Test, FoundationOne®Liquid ...
Business Wire

Foundation Medicine Announces Expanded Participation in National Cancer Institute’s ComboMATCH Platform Trials Through Inclusion of Its High-Quality Blood-Based Biomarker ...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced its expanded participation with the National Cancer Institute (NCI) and ...